CurrentCareSourcePolicy N/A

UTILIZATION MANAGEMENT MEDICAL POLICY

Policy governs coverage recommendation for Exondys 51 (eteplirsen intravenous infusion) for treatment of Duchenne muscular dystrophy (DMD) with DMD gene mutations amenable to exon 51 skipping. It summarizes evidence, guideline context, and issues a coverage stance (not recommended) with no recommended authorization criteria or automation.

Policy Summary

PayerCareSource

PolicyUTILIZATION MANAGEMENT MEDICAL POLICY

Policy CodePolicy N/A

Change TypeAnnual revision (no criteria changes)

Effective Date

Next Review Date

Key ActionGenetic testing for a DMD mutation in blood is always required to characterize the mutation; expect coverage requests for Exondys 51 to be denied based on lack of demonstrated clinical benefit.

SourceLink

POLICY UPDATE CHANGES

Annual revisions with 'No criteria changes' recorded for 04/26/2023, 05/15/2024, and 04/30/2025.

13%Proportion amenable to exon 51 skipping

1 in 3,600–6,000DMD birth prevalence (male newborns)

Oct 2026FDA-required trial completion

NoClinical benefit established

Coverage Summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

This policy governs coverage for Exondys 51 (eteplirsen) — an antisense oligonucleotide intravenous infusion — when used to treat Duchenne muscular dystrophy (DMD) in patients with DMD gene mutations amenable to exon 51 skipping. Exondys 51 received FDA accelerated approval based on an increase in dystrophin in some treated patients, but a clinical benefit has not been established. The policy’s current coverage stance is not recommended / not covered because clinical efficacy data are inadequate. Guidelines require genetic testing to fully characterize the DMD mutation to determine amenability to exon 51 skipping. Key statistics from the policy: approximately 13% of DMD patients are amenable to exon 51 skipping; DMD birth prevalence is about 1 in 3,600–6,000 male infants; the FDA-required randomized, controlled confirmatory trial has an anticipated completion of October 2026; and the policy concludes that clinical benefit is not established.

Key Facts

DrugExondys 51 (eteplirsen)

IndicationDuchenne muscular dystrophy with mutations amenable to exon 51 skipping

Coverage StanceNot recommended / Not covered (clinical benefit not established)

FDA StatusAccelerated approval; confirmatory trial required

Anticipated confirmatory trial completionOct 2026

Proportion amenable13%

Birth prevalence (males)1 in 3,600–6,000

Policy Statement — Conditions Not Recommended for Approval

Policy Statement / Conditions Not Recommended for Approval

Approval is not recommended for Exondys 51 for the following conditions due to lack of demonstrated clinical benefit:

Duchenne Muscular Dystrophy (DMD) — Exondys 51 is not recommended for approval due to unclear clinical benefit and lack of clinical efficacy data.

Limitations cited include: small numbers with dystrophin increase, methodological shortcomings in biopsy data, pivotal trials only in ambulatory patients (unknown benefit in more advanced disease), inadequate information on cardiac and respiratory benefit, and inability to demonstrate alteration or delay of disease progression.

Systematic review and meta-analysis do not show benefit of exon-skipping therapies for DMD; FDA required randomized controlled post-marketing trial with anticipated completion October 2026.

Scope Limitation: Coverage not recommended for any circumstances not listed in Recommended Authorization Criteria (none provided); criteria will be updated as new published data are available.

Medical-Necessity Criteria

The brief contains no Recommended Authorization Criteria — the policy explicitly states there are none and provides no approved initial or continuation authorization criteria. As a result, requests for Exondys 51 are expected to be denied under this policy due to lack of demonstrated clinical benefit. The policy indicates that authorization criteria will be updated if new published data become available.

Provider Actions & Operational Impact

Documentation Required

Genetic testing required for DMD diagnosis

Genetic testing of a blood sample is always required to fully characterize the DMD mutation and determine eligibility for mutation-specific therapies or trials. If no mutation is identified but the patient has signs or symptoms of DMD, a muscle biopsy is clinically indicated.

Denial Risk

Coverage denial for Exondys 51

Approval is not recommended for Exondys 51 and requests are expected to be denied due to lack of established clinical benefit and absence of recommended authorization criteria in the policy.

Background & Evidence Summary

Eteplirsen (Exondys 51) is an antisense oligonucleotide designed to bind exon 51 of dystrophin pre-mRNA to induce exon 51 skipping, producing an in‑frame transcript that can restore dystrophin production in patients with appropriate DMD gene deletions. It received accelerated FDA approval based on observed increases in skeletal muscle dystrophin in some treated patients, but a clinical benefit has not been established. Duchenne muscular dystrophy is an X-linked recessive disorder caused primarily by large frame-shift deletions in the DMD gene that result in loss of dystrophin. Clinical guidelines note that genetic testing from a blood sample is always required to characterize the mutation and determine eligibility for mutation-specific therapies or trials; if no mutation is identified but clinical signs suggest DMD, muscle biopsy is indicated.

Measure	Value
Mean change in 6MWT at Week 24 (Phase II small study)	Placebo −25.8m; Exondys 51 30 mg/kg −128.2m; Exondys 51 50 mg/kg −0.3m
Average dystrophin after 180 weeks	0.93% of healthy subjects
Dystrophin after 48 weeks	0.44% ± 0.43% of healthy subjects; median increase 0.1%
Long-term FVC%p change	Decrease 2.3% per year with Exondys 51 vs 4.1% in natural history cohort

Systematic review evidence summarized in the policy does not show a benefit of exon-skipping therapies for DMD. The FDA has required a randomized, controlled post-marketing trial to establish efficacy for Exondys 51; the policy notes the trial’s anticipated completion of October 2026.

Definitions

Definitions:

Exondys 51: Eteplirsen intravenous infusion, an antisense oligonucleotide designed to induce exon 51 skipping in dystrophin pre-mRNA.

DMD amenable to exon 51 skipping: DMD gene deletions predicted to be responsive to exon 51 skipping that would produce an in-frame transcript and potentially restore dystrophin production in applicable patients.

Revision History

04/26/2023annual_revision

Annual revision with no criteria changes; review date updated to 04/26/2023; policy statement remained unchanged (approval not recommended).

05/15/2024annual_revision

Annual revision with no criteria changes; review date updated to 05/15/2024; policy statement remained unchanged (approval not recommended).

04/30/2025annual_revisionLatest

Annual revision with no criteria changes; review date updated to 04/30/2025; policy statement remained unchanged (approval not recommended).